Navigation Links
Who's patenting whose genome?
Date:12/6/2013

An international project has developed a free and open public resource that will bring much-needed transparency to the murky and contentious world of gene patenting.

In a paper from Cambia and Queensland University of Technology (QUT) published in this week's Nature Biotechnology journal, researchers revealed that overworked patent offices are struggling to keep up with the rapid explosion in information and technology that genetic sequences represent.

"Apparently, many patent offices have no way of tracking genetic sequences disclosed in patents and currently do not provide them in machine-searchable format," said principal author Professor Osmat Jefferson, a QUT academic who leads an international team analysing biological patents for the open-access web resource, The Lens.

"This likely means patents are being granted for genes that are not 'newly discovered' at all, because the patent offices have no way of really knowing."

Professor Jefferson said patenting the genes and proteins of humans and other living things had fallen under intense scrutiny since the US Supreme Court ruled in June this year that naturally occurring genetic material could not be patented.

"Gene patenting is an area where almost everyone has an opinion - passions run high but until now the evidence has been lacking," Professor Jefferson said.

"What is happening? Who's doing the patenting? Why are they doing it? How much are they doing it? What rights are being granted? And how much is our society benefiting from these biological patent teachings? "No one really knows because the whole system is opaque."

The Cambia/QUT team found that while major patent offices claimed to use sophisticated search tools and databases to access patent-disclosed sequences, those search mechanisms are not generally available to the public and may not be accessible to the dozens of patent offices in jurisdictions with limited budgets or emerging intellectual property protection.

The study also painstakingly classified the supposed 'claims' of more than two thousand US patents and found the majority did not actually claim the gene sequence itself, but rather its use for particular purposes.

"A patent is a government grant of a limited exclusive right to try to stop others' use of an invention," Professor Jefferson said.

"When that invention is a gene or protein sequence present in a living organism, it raises serious social questions that deserve serious consideration, especially when that sequence is used for an important genetic test or diagnostic."

Cambia's open sourced PatSeq toolkit, which forms part of its global web resource The Lens, provides the first open public insight into this contentious practice, using sequences extracted from millions of global patent documents, coupled with cutting edge web-based software.

Launched at a gathering in Australia this week, The Lens' PatSeq database already holds more than 120 million DNA sequences and 10 million protein sequences drawn from patent documents.

The PatSeq toolkit allows anyone to explore, at no cost, who has sought patents over genes and proteins in any organism, and includes:

  • a graphical tool to visualise the scope of patents overlaying the human genome
  • an analysing tool which allows detailed findings to the finest level to be correlated with the patent document
  • a search tool that allows anyone with a gene or protein sequence to find matches in the PatSeq database.

"Perhaps the toolkit's most important feature is that all findings can be embedded and shared with anyone, anywhere at no cost, allowing researchers, policy makers and concerned citizens to explore the evidence underlying this practice," Professor Jefferson said.

"The public and indeed enterprise and policy makers need to know the answers if we're to have a transparent, fair and economically productive society."


'/>"/>

Contact: Kate Haggman
kate.haggman@qut.edu.au
61-731-380-358
Queensland University of Technology
Source:Eurekalert

Related biology news :

1. Whats in a genome?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... LONDON , June 2, 2016 ... has awarded the 44 million US Dollar project, ... Security Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... world leader in the production and implementation of Identity Management ... in January, however Decatur was selected ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: